SuperworthOrganon free cash flow OGN
Cash from operations less capital spending, by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- $567M
- Latest quarter, Q2 FY26
- $65M
- −64% on a year earlier
- Fiscal year 2025
- $538M
- −30% on the year before
Organon's free cash flow was $567M over the twelve months to Jun 30, 2026, down 14% on a year earlier.
In its latest quarter, Q2 FY26, it was $65M, down 64% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 23% a year on average.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | $538M | −30% |
| FY2024 | $764M | +39% |
| FY2023 | $548M | −17% |
| FY2022 | $662M | −66% |
| FY2021 | $2B | −3% |
| FY2020 | $2B | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $65M | −64% | $567M | |
| Q1 FY26 | $188M | +337% | $683M | |
| Q4 FY25 | $96M | −71% | $538M | |
| Q3 FY25 | $218M | +120% | $777M | |
| Q2 FY25 | $181M | −40% | $658M | |
| Q1 FY25 | $43M | +43% | $777M | |
| Q4 FY24 | $335M | +5% | $764M | |
| Q3 FY24 | $99M | −52% | $747M | |
| Q2 FY24 | $300M | n/a | $854M | |
| Q1 FY24 | $30M | −56% | $510M | |
| Q4 FY23 | $318M | +56% | $548M | |
| Q3 FY23 | $206M | −21% | $434M |
Against its peers
Companies in Drug Manufacturers - General nearest Organon's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| OGNOrganon | 15.7% |
| LQDALiquidia | 3.9% |
| ARQTArcutis Biotherapeutics | 1.0% |
| INDVIndivior Pharmaceuticals | −2.7% |
| NRIXNurix Therapeutics | 13.4% |
| PBHPrestige Consumer Healthcare | 10.4% |
| KNSAKiniksa Pharmaceuticals International | 3.1% |
| LGNDLigand Pharmaceuticals | 2.2% |
| HRMYHarmony Biosciences | n/m |
| AMRXAmneal Pharmaceuticals | 2.0% |
| ALKSAlkermes plc. | 3.0% |
| Peer median | 3.0% |
Where Organon ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Organon
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.